aTyr Pharma Inc (ATYR) Stock Analysis
Verdict: AVOID
Failed Phase 3 data and partner exit leave ATYR burning $10M+/quarter with an inevitable reverse split and high dilution risk.
Investment score: 25/100
Analysis as of
Is aTyr Pharma Inc stock worth reviewing? The TradeMates thesis
The model evaluates aTyr Pharma as an AVOID due to severe Phase 3 trial setbacks, partner termination, ongoing cash burn, sub-$1 delisting risk, and imminent equity dilution risk.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
aTyr Pharma Inc opportunities and risks
What speaks for ATYR
- FDA protocol alignment reached on September 24, 2026, for a new Phase 3 trial in pulmonary sarcoidosis.
What speaks against ATYR
- Severe equity dilution risk required to finance the newly planned global Phase 3 study.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ATYR | n/a | 94.9x | n/a | -11967.9% | -32003.7% | -304.1% |
| ESLA | n/a | 0.0x | n/a | 0.0% | 0.0% | -40.3% |
| KYNB | 0.1x | 4.7x | 0.3x | 18.2% | 3967.8% | -175.4% |
| ACUT | n/a | 24.1x | n/a | 100.0% | -1680.0% | -50.8% |
| NEUP | n/a | 15.3x | 0.2x | 43.5% | -1578.4% | -68970.2% |
| JSPR | n/a | 0.0x | n/a | 0.0% | 0.0% | -340.8% |
| Peer median | n/a | 4.7x | n/a | 18.2% | 0.0% | -175.4% |
Frequently asked questions about aTyr Pharma Inc (ATYR)
Is ATYR stock a good investment?
The TradeMates model rates aTyr Pharma Inc as AVOID with an investment score of 25/100. The model evaluates aTyr Pharma as an AVOID due to severe Phase 3 trial setbacks, partner termination, ongoing cash burn, sub-$1 delisting risk, and imminent equity dilution risk. This is algorithmic model output, not personal investment advice.
Is ATYR stock a buy?
The TradeMates model verdict for ATYR is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.